Collaborative Fund Advisors LLC decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 67.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,165 shares of the company’s stock after selling 4,446 shares during the period. Collaborative Fund Advisors LLC’s holdings in Neurocrine Biosciences were worth $307,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in NBIX. BlackRock Inc. bought a new stake in Neurocrine Biosciences during the 2nd quarter worth about $2,310,886,000. Bank of New York Mellon Corp bought a new position in shares of Neurocrine Biosciences in the second quarter worth about $117,827,000. Ieq Capital LLC bought a new position in shares of Neurocrine Biosciences in the second quarter worth about $107,914,000. Bank of America Corp DE bought a new position in shares of Neurocrine Biosciences in the second quarter worth about $104,382,000. Finally, Man Group plc acquired a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $101,293,000. Institutional investors and hedge funds own 92.59% of the company’s stock.
Neurocrine Biosciences News Summary
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
- Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
- Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
- Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
- Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks
Insider Activity at Neurocrine Biosciences
In other Neurocrine Biosciences news, insider David W. Boyer sold 826 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.45, for a total transaction of $130,053.70. Following the sale, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. This trade represents a 8.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the transaction, the chief financial officer directly owned 42,808 shares in the company, valued at approximately $6,729,417.60. The trade was a 5.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 18,137 shares of company stock worth $2,829,332. 4.60% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on NBIX. Wells Fargo & Company boosted their price objective on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $204.00 target price on shares of Neurocrine Biosciences in a research note on Friday, October 16th. TD Cowen lifted their price target on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Morgan Stanley boosted their price target on shares of Neurocrine Biosciences from $183.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Finally, UBS Group cut their price objective on shares of Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $202.32.
Get Our Latest Research Report on Neurocrine Biosciences
Neurocrine Biosciences Price Performance
Neurocrine Biosciences stock opened at $159.76 on Friday. The company’s 50 day simple moving average is $147.04 and its 200 day simple moving average is $147.90. The firm has a market capitalization of $16.17 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 0.74 and a beta of 0.36. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the business earned $2.04 EPS. The firm’s revenue was up 41.3% on a year-over-year basis. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 7.66 EPS for the current fiscal year.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.
Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.
Featured Articles
- Five stocks we like better than Neurocrine Biosciences
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
